# Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

> **NCT03893890** · — · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 8 (actual)

## Conditions studied

- Edematous Fibrosclerotic Panniculopathy

## Interventions

- **BIOLOGICAL:** Previously Treated with EN3835

## Key facts

- **NCT ID:** NCT03893890
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-28
- **Primary completion:** 2019-06-25
- **Final completion:** 2019-06-25
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2019-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03893890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03893890, "Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03893890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*